167 related articles for article (PubMed ID: 23504337)
1. High expression of survivin in sacral chordoma.
Chen C; Yang HL; Chen KW; Wang GL; Lu J; Yuan Q; Gu YP; Luo ZP
Med Oncol; 2013 Jun; 30(2):529. PubMed ID: 23504337
[TBL] [Abstract][Full Text] [Related]
2. Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma.
Chen KW; Yang HL; Lu J; Wang GL; Ji YM; Wu GZ; Zhu LF; Liu JY; Chen XQ; Gu YP
J Neurooncol; 2011 Feb; 101(3):357-63. PubMed ID: 20549300
[TBL] [Abstract][Full Text] [Related]
3. High expression of SPHK1 in sacral chordoma and association with patients' poor prognosis.
Zhang K; Chen H; Wu G; Chen K; Yang H
Med Oncol; 2014 Nov; 31(11):247. PubMed ID: 25260803
[TBL] [Abstract][Full Text] [Related]
4. Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis.
Chen K; Mo J; Zhou M; Wang G; Wu G; Chen H; Zhang K; Yang H
Med Oncol; 2014 Apr; 31(4):886. PubMed ID: 24535608
[TBL] [Abstract][Full Text] [Related]
5. C-reactive protein as a prognostic factor in patients with chordoma of lumbar spine and sacrum--a single center pilot study.
Hobusch GM; Bodner F; Walzer S; Marculescu R; Funovics PT; Sulzbacher I; Windhager R; Panotopoulos J
World J Surg Oncol; 2016 Apr; 14():111. PubMed ID: 27091202
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence.
Zhang K; Chen H; Zhang B; Sun J; Lu J; Chen K; Yang H
Int J Clin Exp Pathol; 2015; 8(1):608-14. PubMed ID: 25755752
[TBL] [Abstract][Full Text] [Related]
7. Analysis of risk factors for recurrence after the resection of sacral chordoma combined with embolization.
Yang H; Zhu L; Ebraheim NA; Liu X; Castillo S; Tang T; Liu J; Cui H
Spine J; 2009 Dec; 9(12):972-80. PubMed ID: 19800296
[TBL] [Abstract][Full Text] [Related]
8. Examination of survivin expression in 50 chordoma specimens--A histological and in vitro study.
Froehlich EV; Rinner B; Deutsch AJ; Meditz K; Knausz H; Troppan K; Scheipl S; Wibmer C; Leithner A; Liegl B; Lohberger B
J Orthop Res; 2015 May; 33(5):771-8. PubMed ID: 25640185
[TBL] [Abstract][Full Text] [Related]
9. Recurrence and survival factors analysis of 171 cases of sacral chordoma in a single institute.
Yang Y; Niu X; Li Y; Liu W; Xu H
Eur Spine J; 2017 Jul; 26(7):1910-1916. PubMed ID: 27942938
[TBL] [Abstract][Full Text] [Related]
10. Sacral chordoma: a clinical review of 101 cases with 30-year experience in a single institution.
van Wulfften Palthe ODR; Tromp I; Ferreira A; Fiore A; Bramer JAM; van Dijk NC; DeLaney TF; Schwab JH; Hornicek FJ
Spine J; 2019 May; 19(5):869-879. PubMed ID: 30445184
[TBL] [Abstract][Full Text] [Related]
11. What Are the Conditional Survival and Functional Outcomes After Surgical Treatment of 115 Patients With Sacral Chordoma?
Ji T; Guo W; Yang R; Tang X; Wang Y; Huang L
Clin Orthop Relat Res; 2017 Mar; 475(3):620-630. PubMed ID: 26975382
[TBL] [Abstract][Full Text] [Related]
12. Expression of far upstream element-binding protein 1 correlates with c-Myc expression in sacral chordomas and is associated with tumor progression and poor prognosis.
Wen H; Ma H; Li P; Zheng J; Yu Y; Lv G
Biochem Biophys Res Commun; 2017 Sep; 491(4):1047-1054. PubMed ID: 28780352
[TBL] [Abstract][Full Text] [Related]
13. Surgical treatment of sacral chordoma: survival and prognostic factors.
Ruosi C; Colella G; Di Donato SL; Granata F; Di Salvatore MG; Fazioli F
Eur Spine J; 2015 Nov; 24 Suppl 7():912-7. PubMed ID: 26458933
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of CD40 in sacral chordomas and its correlation with low tumor recurrence.
Li X; Wang S; Chen Y; Liu G; Yang X
Onkologie; 2013; 36(10):567-71. PubMed ID: 24107910
[TBL] [Abstract][Full Text] [Related]
15. Low expression of PHLPP1 in sacral chordoma and its association with poor prognosis.
Chen H; Zhang K; Wu G; Song D; Chen K; Yang H
Int J Clin Exp Pathol; 2015; 8(11):14741-8. PubMed ID: 26823799
[TBL] [Abstract][Full Text] [Related]
16. Current management of sacral chordoma.
Fourney DR; Gokaslan ZL
Neurosurg Focus; 2003 Aug; 15(2):E9. PubMed ID: 15350040
[TBL] [Abstract][Full Text] [Related]
17. Lumbo-sacral chordoma with high-grade malignant cartilaginous and spindle cell components.
Hruban RH; May M; Marcove RC; Huvos AG
Am J Surg Pathol; 1990 Apr; 14(4):384-9. PubMed ID: 1690955
[TBL] [Abstract][Full Text] [Related]
18. Sacral chordoma with unusual posterior radiographic presentation.
Coombs RJ; Coiner L
Skeletal Radiol; 1996 Oct; 25(7):679-81. PubMed ID: 8915056
[TBL] [Abstract][Full Text] [Related]
19. Cytopathological dilemma of anaplastic sacral chordoma with radiological and histological corroboration.
Bandyopadhyay A; Goswami BK; Pramanik R; Majumdar K; Gangopadhyay M
Turk Patoloji Derg; 2011 May; 27(2):157-60. PubMed ID: 21630204
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of immunohistochemical expression of VEGFR2 and iNOS in spinal chordoma.
Akhavan-Sigari R; Gaab MR; Rohde V; Abili M; Ostertag H
Eur Spine J; 2014 Nov; 23(11):2416-22. PubMed ID: 24929808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
